These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28469365)

  • 1. 25-Vitamin D levels in chronic hepatitis C infection: association with cirrhosis and sustained virologic response.
    Backstedt D; Pedersen M; Choi M; Seetharam A
    Ann Gastroenterol; 2017; 30(3):344-348. PubMed ID: 28469365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study.
    Gayam V; Mandal AK; Khalid M; Mukhtar O; Gill A; Garlapati P; Tiongson B; Sherigar J; Mansour M; Mohanty S
    Gastroenterology Res; 2018 Aug; 11(4):309-316. PubMed ID: 30116431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
    Terrier B; Carrat F; Geri G; Pol S; Piroth L; Halfon P; Poynard T; Souberbielle JC; Cacoub P
    J Hepatol; 2011 Oct; 55(4):756-61. PubMed ID: 21334402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.
    Kitson MT; Dore GJ; George J; Button P; McCaughan GW; Crawford DH; Sievert W; Weltman MD; Cheng WS; Roberts SK
    J Hepatol; 2013 Mar; 58(3):467-72. PubMed ID: 23183524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
    Giannini EG; Afdhal NH; Sigal SH; Muir AJ; Reddy KR; Vijayaraghavan S; Elkashab M; Romero-Gómez M; Dusheiko GM; Iyengar M; Vasey SY; Campbell FM; Theodore D
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1301-8. PubMed ID: 25777337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C.
    Enomoto M; Ikura Y; Tamori A; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Murakami Y; Kawada N
    United European Gastroenterol J; 2018 Nov; 6(9):1391-1400. PubMed ID: 30386612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY.
    Torres AD; Sparvoli JMH; Sparvoli AC; Gonçalves CV
    Arq Gastroenterol; 2019; 56(4):394-398. PubMed ID: 31800735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
    Hunyady B; Abonyi M; Csefkó K; Gervain J; Haragh A; Horváth G; Jancsik V; Makkai E; Müller Z; Ribiczey P; Sipos B; Szabó O; Szalay F; Szentgyörgyi L; Tornai I; Újhelyi E; Varga M; Weisz G; Makara M
    Orv Hetil; 2016 Aug; 157(34):1366-74. PubMed ID: 27546804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
    Veldt BJ; Heathcote EJ; Wedemeyer H; Reichen J; Hofmann WP; Zeuzem S; Manns MP; Hansen BE; Schalm SW; Janssen HL
    Ann Intern Med; 2007 Nov; 147(10):677-84. PubMed ID: 18025443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.
    Meissner EG; Kohli A; Virtaneva K; Sturdevant D; Martens C; Porcella SF; McHutchison JG; Masur H; Kottilil S
    J Viral Hepat; 2016 Jul; 23(7):496-505. PubMed ID: 26840694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    BMC Gastroenterol; 2017 Apr; 17(1):54. PubMed ID: 28415985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D deficiency in patients with chronic hepatitis D viral infection.
    Uçmak F; Yılmaz A; Ekin N; Ekinci A; Solmaz İ; Şenateş E
    Clin Exp Hepatol; 2021 Jun; 7(2):141-148. PubMed ID: 34295980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.
    Lange CM; Bojunga J; Ramos-Lopez E; von Wagner M; Hassler A; Vermehren J; Herrmann E; Badenhoop K; Zeuzem S; Sarrazin C
    J Hepatol; 2011 May; 54(5):887-93. PubMed ID: 21145801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
    Kitson MT; Sarrazin C; Toniutto P; Eslick GD; Roberts SK
    J Hepatol; 2014 Dec; 61(6):1247-52. PubMed ID: 25135863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.
    Yu R; Tan D; Ning Q; Niu J; Bai X; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Jia J; Hou J; Xie Q; Sun J
    Hepatol Res; 2018 Feb; 48(3):E213-E221. PubMed ID: 28834607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.
    Fox DS; McGinnis JJ; Tonnu-Mihara IQ; McCombs JS
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1136-1142. PubMed ID: 27869323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.